Compare General Mills, Inc. (GIS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? General Mills, Inc. trades at $32.5 (market cap $17.17B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: General Mills, Inc. is far larger — about 2.3× Spyre Therapeutics Inc. Common Stock's market cap, and General Mills, Inc. pays a 7.6% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 107 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GIS | SYRE | |
|---|---|---|
Market Cap | $17.17B | $7.35B |
Volume | 12,286,564 | 1,624,631 |
Sector | Consumer Staples | Health |
52-Week High | $49.18 | $108.92 |
52-Week Low | $31.67 | $22.18 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $30.35B | $6.35B |
Dividend Yield | 7.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $31.83, down 2.66% amid bearish technical signals and negative profitability metrics. The stock shows mixed earnings performance with a recent Q2 beat but Q4 miss, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. Analyst consensus remains cautious with 61% hold ratings, though the $36 price target suggests 13% upside potential. Recent CEO transition and dividend declaration provide stability signals despite profitability challenges.
The outlook remains challenged by declining margins and negative ROE/ROA, though attractive valuation (P/E 9.2) and dividend yield offer value appeal. Key risks include continued revenue pressure, margin compression, and high debt levels at 45% of assets. Upside depends on successful execution of the $3B savings plan and international growth initiatives.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
